Results 181 to 190 of about 108,249 (257)

Real‐world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone in patients with or without melanoma brain metastasis: Results from the German noninterventional NICO study

International Journal of Cancer, Volume 159, Issue 3, Page 683-698, 1 August 2026.
What's New? Although patients with melanoma brain metastases (MBM) may benefit from treatment with immune checkpoint inhibitors (ICIs), which are known to improve survival in advanced melanoma, MBM patients have often been excluded from trials evaluating ICIs.
Ralf Gutzmer, Michael Weichenthal, Thomas Eigentler, Peter Mohr, Thomas Sickmann, Pia Dücker, Christoffer Gebhardt, Sebastian Haferkamp, Katharina C. Kähler, Friedegund Meier, Claudia Pföhler, Anca Sindrilaru, Patrick Terheyden, Imke von Wasielewski, Selma Ugurel, Jens Ulrich, Jochen Utikal, Carsten Weishaupt, Dirk Schadendorf   +18 more
wiley   +1 more source

ZBP1 mediated restriction of Toxoplasma gondii in both the early acute and chronic brain stages of infection. [PDF]

Immunohorizons
Sibley LA, Babcock IW, Amadi ND, Marchildon AE, Kelly AG, Labuzan SA, Lukens JR, Harris TH.   +7 more
europepmc   +1 more source

Urokinase Plasminogen Activator Receptor‐Associated Protein (uPARAP) as a Potential Next Generation Molecular Target for Treatment of Gastrointestinal Stromal Tumors (GIST)

International Journal of Cancer, Volume 159, Issue 3, Page 797-808, 1 August 2026.
A key component of the collagen internalization and lysosomal degradation cellular machinery, uPARAP may contribute to cancer progression. Here, the authors explored the expression of uPARAP in gastrointestinal stromal tumors using well‐annotated clinical patient samples and specimens from cell line‐ and patient‐derived xenografts.
Chao‐Chi Wang, Flavia Paternostro, Agnieszka Wozniak, Lore De Cock, Luna De Sutter, Kimberly Verbeeck, Ulla Vanleeuw, Daniël Gorgels, Che‐Jui Lee, Raf Sciot, Patrick Schöffski   +10 more
wiley   +1 more source

Durable Disease Control in Disseminated Primary Splenic Leiomyosarcoma Treated With Sequential Gemcitabine-Docetaxel and Pazopanib Therapy: A Case Report. [PDF]

Cureus
Kurbanova S, Sharobiddinov B, Abdusattorova O, Abdusattorov R.   +3 more
europepmc   +1 more source

Sphingosine‐1‐Phosphate Receptor 1 Promotes Ovarian Cancer Tumorsphere Proliferation and Metastasis

International Journal of Cancer, Volume 159, Issue 3, Page 768-781, 1 August 2026.
In high‐grade serous ovarian cancer, malignant ascites frequently arise as ovarian cancer cells shed from the primary tumor and aggregate into tumorspheres, severely limiting treatment success. To date, little is known about the mechanisms governing tumorsphere endurance and metastasis within the ascites once formed.
Núria Gendrau‐Sanclemente, Agnès Figueras, Ferran Medina‐Jover, Juan A. Marín‐Jiménez, Michelle De Leeuw, Tianyu Dai, Marina Moreno‐Mosquera, Andrea Morales, Marc Guiu, Josefina Casas, José Carlos Perales, Roger R. Gomis, Francesc Viñals   +12 more
wiley   +1 more source

Peritoneum

, 2009
John R. Haaga, Perry J. Pickhardt
openaire   +2 more sources

Peritoneal Volume Influence on POCUS Volume Assessment in Patients Undergoing Peritoneal Dialysis. [PDF]

POCUS J
Rincón MM, Barbieri D, de la Manzanara VL, Ferreras ER, Meneses AA, Fernández CF, Ortiz CR, López RL, Calvo JAH, Sanchez-Fructuoso AI.   +9 more
europepmc   +1 more source

Tumor Infiltrating Lymphocyte Therapy Combined With PD‐1/LAG‐3 Inhibition in Patients With Recurrent Platinum‐Resistant Ovarian Cancer

International Journal of Cancer, EarlyView.
The detection of tumor‐infiltrating lymphocytes (TILs) is a positive prognostic factor in ovarian cancer. Moreover, TILs are significantly boosted by immunotherapy, though ovarian cancer patients have seen limited benefit from immune therapies. This study investigated the safety and feasibility of TIL therapy combined with PD‐1 and LAG‐3 inhibitors in ...
Tine J. Monberg, Cathrine L. Lorentzen, Marie C. W. Westergaard, Trine Z. Iversen, Troels H. Borch, Marco Donia, Sigrid M. Mannering, Stine E. W. Banke, Özcan Met, Inge Marie Svane   +9 more
wiley   +1 more source

Minimally Invasive Surgery as a Longitudinal Diagnostic and Restaging Tool in a Recurrent STK11-Altered Adnexal Tumor: A Case Report. [PDF]

Diagnostics (Basel)
Maccio A, Neri M, Vallerino V, Nemolato S, Sole G, Pusceddu E, Ferrari PA.   +6 more
europepmc   +1 more source

The Relevance of Curative‐Intent Metastasectomy in Colorectal Cancer Patients: Real‐World Insights From a Certified Comprehensive Cancer Center in Germany

International Journal of Cancer, EarlyView.
Patients with metastatic colorectal cancer who are ineligible for upfront metastasectomy may still become candidates for secondary metastasectomy with curative intent following response to primary chemotherapy. However, most studies dichotomize metastatic colorectal cancer into resectable and unresectable disease.
Julian W. Holch, Jo‐Ann Eisenburger, Antony Weber, Iris Kammermeier‐Wehlau, Yannick Wiberg, Fabian Allmendinger, Kathrin Heinrich, Lena Weiss, C. Benedikt Westphalen, Victoria Krenmayr, Klara Dorman, Danmei Zhang, Theres Fey, Karin Berger‐Thürmel, Ulrich Wirth, Florian Kühn, Michael von Bergwelt‐Baildon, Jens Werner, Volker Heinemann   +18 more
wiley   +1 more source